Prometheus: A Platform for Rapid Development of Human Antibody-based Therapeutics and Prophylactics against Emerging Viral Threats

Project: Research project

Project Details

Description

No FDA-approved treatments exist for ebolaviruses, Crimean-Congo hemorrhagic fever virus (CCHFV), and the Andes and Sin Nombre hantaviruses, which are responsible for severe dis- ease in humans. The Prometheus CETR will develop and deliver treatments against each of these groups of viruses that are based on antibodies—natural immunity proteins speci?c for these viruses—isolated from humans who have recovered from infection. Such natural anti- body-based treatments can be more easily developed into drugs to treat people and with fewer risks of side effects.
StatusActive
Effective start/end date2/14/191/31/23

Funding

  • National Institute of Allergy and Infectious Diseases: $4,452,397.00
  • National Institute of Allergy and Infectious Diseases: $4,348,829.00
  • National Institute of Allergy and Infectious Diseases: $4,390,495.00
  • National Institute of Allergy and Infectious Diseases: $4,357,599.00

Fingerprint

Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.